This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Volpi, A. Articles by Tognoni, G. Search for Related Content PubMed PubMed Citation Articles by Volpi, A. Articles by Tognoni, G.

Circulation, Vol 82, 1279-1288, Copyright © 1990 by American Heart Association

ARTICLES

Incidence and prognosis of secondary ventricular fibrillation in acute myocardial infarction. Evidence for a protective effect of thrombolytic therapy. GISSI Investigators

A Volpi, A Cavalli, E Santoro and G Tognoni
Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico, Milan.

The multicenter randomized study of the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico has provided the opportunity to analyze the impact of thrombolytic treatment on secondary ventricular fibrillation incidence in a large population of patients (11,712) with acute myocardial infarction. A reduction of about 20% in the frequency of secondary ventricular fibrillation was observed among patients allocated to thrombolytic treatment (streptokinase, 2.4% versus control, 2.9%; relative risk, 0.80; 95% confidence interval, 0.64-1.00). Streptokinase appeared to exert its protective effect specifically in patients treated within 3 hours of onset of symptoms (streptokinase, 2.6% versus control, 3.7%; relative risk, 0.71; 95% confidence interval, 0.53-0.95). This protection was essentially due to a reduced incidence of late ventricular fibrillation occurring after the first day of hospitalization. The 311 patients with secondary ventricular fibrillation represented an overall incidence of 2.7%. Such incidence was not related to infarct location or sex but was significantly more common in patients older than 65 years (3.3% versus 2.3% in younger patients). A significant excess of in-hospital deaths was found in patients with secondary ventricular fibrillation compared with those in the reference group (38% versus 24%; relative risk, 1.98; 95% confidence interval, 1.56-2.52). Conversely, secondary ventricular fibrillation was not a predictor of 1-year mortality for hospital survivors. Thrombolytic treatment with intravenous streptokinase affords protection against secondary ventricular fibrillation most probably by a limitation of infarct size. When the arrhythmia complicates the course of infarction, it is associated with an adverse short-term outcome, whereas the long-term prognosis is not influenced.

This article has been cited by other articles:

				R. H. Mehta, A. Z. Starr, R. D. Lopes, J. S. Hochman, P. Widimsky, K. S. Pieper, P. W. Armstrong, C. B. Granger, and for the APEX AMI Investigators Incidence of and Outcomes Associated With Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention JAMA, May 6, 2009; 301(17): 1779 - 1789. [Abstract] [Full Text] [PDF]

				O. Goktekin, M. Melek, B. Gorenek, A. Birdane, G. Kudaiberdieva, Y. Cavusoglu, and B. Timuralp Cardiac Troponin T and Cardiac Enzymes After External Transthoracic Cardioversion of Ventricular Arrhythmias in Patients With Coronary Artery Disease Chest, December 1, 2002; 122(6): 2050 - 2054. [Abstract] [Full Text] [PDF]

				N. Sotoodehnia, A. Zivin, G. H Bardy, and D. S Siscovick Reducing mortality from sudden cardiac death in the community: lessons from epidemiology and clinical applications research Cardiovasc Res, May 1, 2001; 50(2): 197 - 209. [Abstract] [Full Text] [PDF]

				M Lund, J.K French, R.N Johnson, B.F Williams, and H.D White Serum troponins T and I after elective cardioversion Eur. Heart J., February 1, 2000; 21(3): 245 - 253. [Abstract] [PDF]

				K. H. Newby, T. Thompson, A. Stebbins, E. J. Topol, R. M. Califf, and A. Natale Sustained Ventricular Arrhythmias in Patients Receiving Thrombolytic Therapy : Incidence and Outcomes Circulation, December 8, 1998; 98(23): 2567 - 2573. [Abstract] [Full Text] [PDF]